Virpax Pharmaceuticals logo
Virpax Pharmaceuticals VRPX
$ 0.58 -1.19%

Quarterly report 2024-Q3
added 11-14-2024

report update icon

Virpax Pharmaceuticals Balance Sheet 2011-2024 | VRPX

Annual Balance Sheet Virpax Pharmaceuticals

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - - 489 K 1.22 M 452 K - - - - - - -

Long Term Debt

- - - - - - - - - - - - -

Long Term Debt Current

- - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - -

Total Current Liabilities

7.69 M 3.09 M 2.09 M - - - - - - - - - -

Total Liabilities

7.69 M 3.09 M 2.09 M 1.02 M 2.78 M 1.25 M - - - - - - -

Deferred Revenue

- - - - - - - - - - - - -

Retained Earnings

-59.5 M -44.4 M -22.7 M - -6.31 M -3 M - - - - - - -

Total Assets

9.63 M 19.7 M 39.6 M 465 K 46.7 K 61.5 K - - - - - - -

Cash and Cash Equivalents

9.14 M 19 M 36.8 M 54.8 K - - - - - - - - -

Book Value

1.93 M 16.6 M 37.5 M -556 K -2.73 M -1.19 M - - - - - - -

Total Shareholders Equity

1.93 M 16.6 M 37.5 M - - - - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Virpax Pharmaceuticals

2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - - - - - - - - - - 1.07 M 1.07 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - - - - - - - - - - 1.02 M 1.02 M 1.02 M - 1.02 M 1.02 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

2.36 M 5.39 M 4.34 M 7.69 M 6.53 M 3.65 M 3.29 M 3.09 M 4.21 M 2.48 M 2.19 M 2.09 M 1.81 M 3.85 M 3.66 M 4.68 M 4.68 M 4.68 M 4.68 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-68.2 M -66.2 M -62.8 M -59.5 M -55 M -49 M -45.9 M -44.4 M -41.4 M -33.7 M -27.8 M -22.7 M -18.6 M -15.4 M -13 M -10.6 M -10.6 M -10.6 M -10.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

304 K 2.59 M 3.13 M 9.63 M 13 M 16 M 18.5 M 19.7 M 23.6 M 29.4 M 34.7 M 39.6 M 43.3 M 11.4 M 13.2 M 465 K 465 K 465 K 465 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

17.2 K 1.87 M 1.87 M 9.14 M 12.2 M 14.8 M 17 M 19 M 20.6 M 26.1 M 30.8 M 36.8 M 41.7 M 10.5 M 12.3 M 54.8 K 257 K 54.8 K 54.8 K 41.5 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

-2.05 M -2.79 M -1.21 M 1.93 M 6.51 M 12.3 M 15.2 M 16.6 M 19.4 M 26.9 M 32.6 M 37.5 M 41.5 M 7.54 M 9.56 M -4.22 M -4.22 M -4.22 M -4.22 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

-2.05 M -2.79 M -1.21 M 1.93 M 6.51 M 12.3 M 15.2 M 16.6 M 19.4 M 26.9 M 32.6 M 37.5 M 41.5 M 7.54 M 9.56 M -4.22 M -4.22 M -4.22 M -4.22 M -2.73 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency